GLP-1 Evidence is part of a network of independent reference sites published by one person. GLP-1 Evidence tracks the clinical literature on GLP-1 and dual-agonist drugs — efficacy, body composition, cardiovascular outcomes, side effects, and what happens when people stop. Every claim is tied to a PubMed record.
How a page gets researched
We define the question the way a reader would search for it, not the way a journal would phrase it.
We pull the literature from PubMed, weighting meta-analyses, systematic reviews, randomised trials and clinical guidelines above everything else.
We read the abstracts and, where access allows, the full text — with attention to sample size, duration, funding and whether the outcome measured is the outcome you care about.
We write the answer, then attach the citations to the specific sentences they support.
We re-check pages when a major trial or guideline lands.
What we are not
This is not medical advice, and it is not a substitute for a clinician who knows your history. Nutrition and drug research is noisy, effect sizes in free-living humans are usually smaller than the headline suggests, and almost every finding here is an average that may not describe you.
Corrections
If you find an error, tell us and we will fix it and note the change on the page.